Integrated Evidence that Holds Up Across a Hematologic Oncology Treatment Portfolio

Supporting complex efficacy assessment, managing portfolio risk, and meeting overlapping database lock deadlines for a novel CLL development program

A leading pharmaceutical company was advancing a novel BTK inhibitor for chronic/small lymphocytic leukemia (CLL/SLL) through a portfolio of four concurrent Phase III studies when multiple analysis deliverables and database lock milestones began converging. In CLL/SLL, efficacy assessment depends on integrating imaging findings with clinical and laboratory data, adding complexity to blinded independent central review (BICR) workflows and increasing the operational risk associated with critical development milestones.

Perceptive Imaging provided imaging core lab support, integrated clinical dossier reviews, and proactive workflow planning to help the sponsor maintain lock readiness across its development portfolio. Data from one Perceptive-supported Phase III
CLL study contributed to the evidence package associated with an FDA approval for the novel BTK inhibitor, demonstrating the importance of rigorous, integrated imaging and clinical data review processes in hematologic oncology drug development.